Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (August 2019)
51 slides from Evogene's investor presentation, August 2019

Slide 1: Evogene at a Glance
August, 2019 EVOGENE AT A GLANCE… Ofer Haviv, President & CEO

Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains "forward-looking statements" relating to All written and oral forward-looking statements attributable to us or future events, and we may from time to time make other statements, persons acting on our behalf are expressly qualified in their entirety by

Slide 3: Agenda
AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 3

Slide 4: What We Do
WHAT WE DO… We revolutionize the product development …through the use of a unique Computational process in life-science based markets… Predictive Biology (CPB) platform 4

Slide 5: Agenda
AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 5

Slide 6: The Challenge
THE CHALLENGE Product development common practice Product Successful Definition Product Launch Efficacy Stability Shelf-life Safety Candidates mainly addressing the first criterion Low probability of success Long time to market High development costs Limited ‘next generation’ products in pipelines 6

Slide 7: The Desired Solution
THE DESIRED SOLUTION Candidates with the highest probability of success Product Definition Successful Product Launch Efficacy Stability Shelf-life Safety Candidates mainly addressing the first criterion • Increasing probability of success Successful • Reducing time to Product Launch market Candidate

Slide 8: Evogene's Unique Product Development Approach
EVOGENE’S UNIQUE PRODUCT DEVELOPMENT APPROACH Product Definition Successful Product Launch Efficacy Stability Shelf-life Safety Candidates mainly addressing the first criterion The CPB platform • Increasing Tailored big data probability of Science Interconnected data hub success Analysis platforms S

Slide 9: Prediction of Candidates for Life-Science Based Products
PREDICTION OF CANDIDATES FOR LIFE-SCIENCE BASED PRODUCTS Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders* Genetic Bacterial genes – toxins for insects Elements Essential genes – target for herbicides

Slide 10: Agenda
AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 10

Slide 11: Targeted Markets
TARGETED MARKETS Biotechnology for life science industries Green - Agriculture Castor oil White- Industrial Ag-Biologicals • Industrial application • Ag-Chemicals • Polymers • Seeds • Enzymes Ag-Chemicals • Ag-Biologicals • Bacteria • Precision Ag • Livestock • Biomaterials Seed Traits • Energy Medi

Slide 12: Agenda
AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 12

Slide 13: Corporate Structure & Activities
CORPORATE STRUCTURE & ACTIVITIES CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stabilit

Slide 14: Corteva to Invest in Lavie Bio
& CORTEVA N X gene Corteva Agriscience to Invest in Evogene’s Agriculture Biologicals Subsidiary, Lavie Bio Investment Includes Equity and Corteva’s Shares in Taxon Biosciences for Shares in Lavie Bio Wilmington, Del., USA and Rehovot, Israel — Aug. 7, 2019 — Corteva, Inc. (NYSE: CTVA), a leading pu

Slide 15: Main Collaborations
MAIN COLLABORATIONS CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil CASA 15

Slide 16: Milestone Roadmap
MILESTONE ROADMAP Enter new collaboration agreement Reach ‘Lead’ in herbicide program Enter pre-clinical trials in 2 additional Complete first pre-clinical study in programs; positive results in at least oncology one study Complete two cannabis growth cycles Demonstrate first desired cannabis trait

Slide 17: Agenda
AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 17

Slide 18: Evogene at a Glance Summary
EVOGENE AT A GLANCE… SUMMARY WHAT WE DO CORPORATE STRUCTURE We revolutionize the product development process in life-science based Evogene and the CPB platform markets through the use of a unique Computational Predictive Biology at the heart of a group of (CPB) platform. subsidiaries, each focused i

Slide 19: Evogene at a Glance
August, 2019 EVOGENE AT A GLANCE… Ofer Haviv, President & CEO Contact: ir@evogene.com T: +972 8 931 1963

Slide 20: Annex I: Subsidiary Overview
Annex I: Subsidiary Overview 20

Slide 21: Corporate Structure
CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

Slide 22: AgPlenus (Ag-Chemicals) Mission & Products
AGPLENUS (AG-CHEMICALS) MISSION & PRODUCTS MISSION Design effective and sustainable crop protection products by leveraging predictive biology Main Products under development Herbicides –Market size: $25B* (2018), growing market need for novel herbicides with improved safety profile and solution for

Slide 23: Business Model: Delivering De-risked Lead Candidates
BUSINESS MODEL Delivering de-risked lead candidates Lead Continued development & Discovery Optimization regulation AgPlenus strategic focus Target Hit Lead Optimized Lead Starting point for • Indication for • Commercial-level • Commercial-level commercial-level commercial-level efficacy efficacy eff

Slide 24: AgPlenus (Ag-Chemicals) - Pipeline
AGPLENUS (AG-CHEMICALS) - PIPELINE Continued Discovery Lead Optimization development Target Hit Lead Optimized lead Final Novel MoA/SoA product Herbicides Novel model of action (non-selective/selective) 10 product candidates Insecticides Novel site of action broad spectrum 5 targets/sites AI optimiz

Slide 25: Corporate Structure
CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

Slide 26: Lavie Bio (Ag-Biologicals) Mission & Products
LAVIE BIO (AG-BIOLOGICALS) MISSION & PRODUCTS MISSION Improve food quality, health and sustainability through the introduction of microbiome based ag-biologicals products Products under development: Bio-Stimulant – Market size: $2B* (2016), Microbial based targeting yield improvement in row crops su

Slide 27: Business Model
BUSINESS MODEL Pre. Early Development Development Discovery Development Stage 1 Stage 2 Commercializatio n Fragmented Distribution markets A channels Consolidated markets B Partner Model A – Direct Market Access Model B – Market Access via partner Co-development of corn bio-stimulants with Corteva 2

Slide 28: Lavie Bio (Ag-Biologicals) - Pipeline
LAVIE BIO (AG-BIOLOGICALS) - PIPELINE Commerciali Product program Application Discovery Early Dev. Dev.stage 1 Dev. stage 2 Product zation Bio Stimulants Yield improvement Seed Corn under normal treatment & drought Yield improvement Seed Wheat under normal treatment & drought Bio Pesticides Protect

Slide 29: Corporate Structure
CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

Slide 30: Ag Seeds - Mission & Products
AG SEEDS - MISSION & PRODUCTS MISSION Bring to market top-quality seeds with high-value traits, under the “Triple S” Concept – Safe, Secure and Sustainable food Products under development mainly via (i) GMO and (ii) Genome Editing : Insect control traits- Lepidoptera, Coleoptera, Hemiptera Yield and

Slide 31: Insect Control
INSECT CONTROL Discover & develop novel proteins conferring resistance to key insects through new modes of action Diverse trait portfolio with novel Mode of Action ! 31

Slide 32: Insect Control - Example
INSECT CONTROL- EXAMPLE Confirmed protection from Southern Green Stinkbug (STK) in transgenic tomato in 3 experiments WT Exp. 1 Exp. 2 Exp. 3 100 100 100 90 90 90 80 80 80 70 70 70 P = 0.0278 P = 0.0068 P = 0.0001 Survival (%) Survival (%) Survival (%) 60 60 60 EV040030208 50 50 50 40 40 40 30 30 30

Slide 33: Yield and Environmental Stress Product Candidates
YIELD AND ENVIRONMENTAL STRESS PRODUCT CANDIDATES* 18m-24m 4-6 year 2-4 year 1-2 years 1-2 years Phase 1 Phase 2 (Early Phase 3 (Adv. Crop Trait Partner Discovery Dev & Phase IV (POC) Development) Product Regulation) (Pre -Launch) Corn Yield Drought Nitrogen use efficiency Soybean Yield Drought *Tim

Slide 34: Yield and Environmental Stress Collaboration Example: Bayer (Monsanto)
YIELD AND ENVIRONMENTAL STRESS COLLABORATION EXAMPLE BAYER (MONSANTO) Collaboration period - 10 years Key terms - Objective - improved seeds via biotechnology R&D and up-front payments - total ~$68M Crops - corn, soybean, cotton, canola Milestone payments + royalties from sales Traits

Slide 35: Disease Resistance Product Candidates
DISEASE RESISTANCE PRODUCT CANDIDATES* Disease Resistance GMO Product Candidates:* 18m-24m 4-6 year 2-4 year 1-2 years 1-2 years Phase 1 Phase 2 (Early Phase 3 (Adv. Crop Trait Partner Discovery Dev & Phase IV (POC) Development) Product Regulation) (Pre -Launch) Corn Fusarium stalk rot Soybean Asian

Slide 36: Genome Editing Disease Resistance Example
GENOME EDITING DISEASE RESISTANCE EXAMPLE 36

Slide 37: Corporate Structure
CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

Slide 38: Biomica - Mission & Products
BIOMICA – MISSION & PRODUCTS MISSION Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology Products under development: Microbiome and small molecule based therapies for: Immuno-oncology (with ICI) – combination therapy for cancer

Slide 39: Big Biopharma Is Investing More Through Partnerships
BIG BIOPHARMA IS INVESTING MORE THROUGH PARTNERSHIPS Obesity and Inflammatory Ulcerative Crohn’s Inflammatory Inflammatory Gastrointestinal metabolic disease bowel disease Colitis disease bowel disease bowel disease indications 2014 2013 2013 2016 2016 2017 2017 Crohn’s Inflammatory Inflammatory Imm

Slide 40: Pipeline
PIPELINE Program Indication / Target Discovery Preclinical Phase 1 Phase 2 Approach Combination Therapy BMC121 for NSCLC Immuno- oncology (with ICI) Combination Therapy BMC127 for NSCLC MDRO BMC201 C. difficile toxin-B BMC426 IBS GI related BMC321 IBD disorders BMC322 IBD Biological Small Molecule 4

Slide 41: Corporate Structure
CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

Slide 42: Canonic Mission & Products
CANONIC MISSION & PRODUCTS MISSION To develop and bring to market medical grade cannabis through a revolutionary genomic approach Products under development: Innovative products to address key market needs: ▪ MetaYield* - Increased metabolite yield ▪ Unican* - Verified variety stability ▪ Precise* -

Slide 43: Business Model
BUSINESS MODEL Canonic aims to develop elite cannabis varieties for commercialization of medical products directly or via partnerships Potential partnerships Varieties dev. Seed production Cannabis growth Formulation Clinical validation & Unique regulation Seeds Flowers varieties 43

Slide 44: Milestone Roadmap
MILESTONE ROADMAP 2019 2020 2021 ➢ Establishment of R&D ➢ First product trait ➢ Finalize development growing facility demonstrated of first improved variety ➢ Complete two ➢ Complete three cannabis growth cycles cannabis growth cycles ➢ Pre-commercial stage ➢ Establish agronomic ➢ Complete ➢ Seed in

Slide 45: Corporate Structure
CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

Slide 46: Casterra Mission & Products
CASTERRA MISSION & PRODUCTS MISSION Providing stable supply for the growing market demand for castor oil Product: An integrated ag-solution for castor - proprietary castor seed varieties supported by novel agro- technical know-how and proprietary mechanical harvesting. Current Practice: Casterra sol

Slide 47: Business Model and Technological Position
BUSINESS MODEL AND TECHNOLOGICAL POSITION Revenue sharing with oil producers + Partner Partner Variety Seed Grain Oil/Cake Product Breeding technology & Seed production Industrial oil users Grower Crusher genomics Seed sales - Integrated solution (inc. growth protocol & mechanical harvest) Variety S

Slide 48: Pipeline
PIPELINE Israel - E1-E2 Target market – D1-D2 Research / Yield trials & Pre-commercial & Commercial Early screening mechanical Harvesting Pre-Breeding Growth Protocol Portfolio 1st generation: CR-712 Compact architecture, adapted to mechanical harvest, uniformity, high germination rate CR-712 2nd ge

Slide 49: Annex II: Financial Fundamentals
Annex II: Financial Fundamentals 49

Slide 50: Key Financials – Balance Sheet
KEY FINANCIALS – BALANCE SHEET Thousand US $ 30.06.2019 31.12.2018 Key Points: Current Assets 47,795 55,488 ▪ Cash position: ~46 million USD as of 30.06.2019 Long-Term Assets 5,659 3,206 ▪ No debt Total Assets 53,454 58,694 ▪ Estimated net cash usage for 2019: $16-$18 million Current Liabilities 4,7

Slide 51: Key Financials – P&L
KEY FINANCIALS – P&L Thousand US $ H1 2019 H1 2018 Q2 2019 Q2 2018 2018 Revenues 540 745 192 379 1,747 Gross Profit 368 196 91 114 295 Operating Loss (9,372) (9,619) (4,703) (4,673) (19,989) Loss (7,895) (10,155) (4,141) (4,769) (20,812) 51
Source: Internet Archive copy of evogene.com
More decks from Evogene Ltd.
Investor Presentation (August 2026)32 slides · Aug 27, 2026
Q2 2026 Earnings Presentation18 slides · Aug 18, 2026
Investor Presentation (June 2026)32 slides · Jun 16, 2026
Q1 2026 Earnings Presentation27 slides · May 20, 2026
Investor Presentation (April 2026)27 slides · Apr 28, 2026
Investor Presentation (March 2026)26 slides · Mar 12, 2026